Please sign in to follow a disease.
Blood platelet RNA test could revolutionize ovarian cancer detection
NCT ID NCT06665945
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
The SENTRY study is testing whether changes in platelet RNA (a type of genetic material in blood cells) can help diagnose ovarian cancer early. Researchers will collect blood samples from 245 women—those with ovarian masses and healthy volunteers—to see if their new test can accurately tell who has cancer. If it works, this could lead to a simple, non-invasive screening tool for a disease that is often caught too late.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Platelet RNA expression test (diagnostic test)
- What this could lead to
- If successful, this could lead to a simple blood test that helps detect ovarian cancer earlier, when treatment is more likely to work.
- What could go wrong
- This is a small, early-stage study. The test may not be accurate enough in real-world settings, and results may not apply to all women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 245 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will be patients in the Huntsman Cancer Hospital Clinics in Salt Lake City, Utah.
- Ages
-
21 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Study Populations 1 and 2: Women with a Recent Diagnosis of an Ovarian or Pelvic Mass (n=215) Inclusion Criteria: 1. Women aged 21 years or older 2. Diagnosed with any type of ovarian or pelvic mass 3. Treatment naïve for current ovarian cancer (if cancer has been diagnosed) 4. The treating medical provider(s) are planning to perform a biopsy, surgery, or other diagnostic procedure to further evaluate the ovarian or pelvic mass (if not already diagnosed prior to consent) Exclusion Criteria: 1. Any other active malignancy 2. Other diagnosis of any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix. Adjuvant endocrine therapy or other maintenance therapy is allowed. 4. Currently receiving chemotherapy, radiation therapy, or other treatments for ovarian cancer 5. Has already undergone complete ovarian mass resection 6. Unable to provide blood sample Study Population 3: Control Women without Ovarian Cancer (n=30) Inclusion Criteria: 1\. Women aged 21 years or older Exclusion Criteria: 1. Any active malignancy or diagnosis of cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 2. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks 4. Renal failure (defined as eGFR \< 60 mL/min/1.73m² or on dialysis) 5. Liver failure (defined as having hepatic encephalopathy of any degree, OR moderately severe coagulopathy defined as INR ≥ 1.5, OR known cirrhosis, OR ALT of ≥ 10X ULN, OR total bilirubin of ≥ 3.0 mg/dL, OR diagnosis of liver failure) 6. Decompensated or end-stage heart failure (defined as ACC/AHA Stage C or Stage D heart failure) 7. Poorly controlled diabetes mellitus (defined as a HbA1c \> 9.0%) 8. Venous thrombosis, myocardial infarction, or stroke within the last 8 weeks 9. Currently pregnant or have been pregnant within the last 12 weeks 10. Any blood product transfusion within the last 8 weeks 11. Personal history of ovarian cancer at any time 12. History of bilateral salpingo-oophorectomy 13. History of oophorectomy 14. Unable to provide blood sample
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets
- Can inhaled manganese make ovarian cancer immunotherapy hit harder?
- Can a pill shrink Hard-to-Treat ovarian tumors?
- New antibody aims to preserve immune checkpoint while fighting cancer